Processing

Please wait...

Settings

Settings

Goto Application

1. WO2014100883 - HSP70 BINDING COMPOUND, USE, ANTITUMOUR PHARMACEUTICAL COMPOSITION, GENE CONSTRUCT FOR EXPRESSING AN HSP70 BINDER, PRODUCTION PROCESS, PROCESS FOR EVALUATING TUMOUR CELLS, METHOD OF SENSITIZATION OF TUMOUR CELLS TO CHEMOTHERAPEUTIC DRUGS

Publication Number WO/2014/100883
Publication Date 03.07.2014
International Application No. PCT/BR2013/000612
International Filing Date 27.12.2013
IPC
C07K 14/47 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
A61K 38/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
CPC
A61K 33/243
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
243Platinum; Compounds thereof
A61K 33/40
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
40Peroxides
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61K 38/1709
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
1703from vertebrates
1709from mammals
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 9/0019
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Applicants
  • UNIÃO BRASILEIRA DE EDUCAÇÃO E ASSISTÊNCIA, MANTENEDORA DA PUCRS [BR]/[BR]
Inventors
  • CAZABUENA BONORINO, Cristina Beatriz
  • DUARTE DE SOUZA, Ana Paula
Agents
  • REMER VILLAÇA & NOGUEIRA ASSESSORIA E CONSULTORIA DE PROPRIEDADE INTELECTUAL S/S LTDA.
Priority Data
BR 10 2012 033804-128.12.2012BR
Publication Language Portuguese (pt)
Filing Language Portuguese (PT)
Designated States
Title
(EN) HSP70 BINDING COMPOUND, USE, ANTITUMOUR PHARMACEUTICAL COMPOSITION, GENE CONSTRUCT FOR EXPRESSING AN HSP70 BINDER, PRODUCTION PROCESS, PROCESS FOR EVALUATING TUMOUR CELLS, METHOD OF SENSITIZATION OF TUMOUR CELLS TO CHEMOTHERAPEUTIC DRUGS
(FR) COMPOSÉ LIGAND DE HSP70, UTILISATION, COMPOSITION PHARMACEUTIQUE ANTITUMORALE, CONSTRUCTION GÉNÉTIQUE POUR L'EXPRESSION D'UN LIGAND DE HSP70, PROCÉDÉ DE PRODUCTION, PROCÉDÉ D'ÉVALUATION DE CELLULES TUMORALES, MÉTHODE DE SENSIBILISATION DE CELLULES TUMORALES, MÉTHODE DE SENSIBILISATION DE CELLULES TUMORALES À DES AGENTS CHIMIOTHÉRAPEUTIQUES
(PT) COMPOSTO LIGANTE DE HSP70, USO, COMPOSIÇÃO FARMACÊUTICA ANTI-TUMORAL, CONSTRUÇÃO GÊNICA PARA A EXPRESSÃO DE LIGANTE DE HSP70, PROCESSO DE PRODUÇÃO, PROCESSO PARA AVALIAÇÃO DE CÉLULAS TUMORAIS, MÉTODO DE SENSIBILIZAÇÃO DE CÉLULAS TUMORAIS A QUIMIOTERÁPICOS
Abstract
(EN) The present invention provides the use of the HspBP1 protein or portion thereof in preparing an antitumour pharmaceutical composition, the combination thereof with one or more chemotherapeutic agents being optional. The following are also disclosed: a gene construct for expressing said binder, a production process, a process for evaluating tumour cells, and a method of sensitization of tumours to chemotherapeutic drugs. The invention also provides a novel in vivo and in vitro experimental model for developing/evaluating antitumour agents. The pharmaceutical compositions of the invention provide antitumour activity and are highly specific for neoplastic cells, resulting in less cytotoxicity for cells with normal cell division. These and other advantages of the invention characterize a solution for the inconveniences of the currently known chemotherapeutic treatments.
(FR) La présente invention concerne l'utilisation de la protéine HspBP1 ou d'une partie de celle-ci pour la préparation d'une composition pharmaceutique antitumorale, éventuellement en combinaison avec un ou plusieurs agents chimiothérapeutiques. L'invention concerne également : une construction génétique pour l'expression dudit ligand ; un procédé de production ; un procédé d'évaluation de cellules tumorales ; et une méthode de sensibilisation de tumeurs à des agents chimiothérapeutiques. L'invention se rapporte en outre à un nouveau modèle expérimental in vivo et in vitro pour l'élaboration/évaluation d'agents antitumoraux. Les compositions pharmaceutiques de l'invention exercent une action antitumorale et possèdent une haute spécificité pour les cellules néoplasiques, d'où une cytotoxicité réduite contre les cellules à division normale. Ces avantages de l'invention, entre autres, se caractérisent en ce qu'ils offrent une solution aux inconvénients des régimes chimiothérapeutiques actuellement connus.
(PT) A presente invenção proporciona o uso da proteína HspBP1 ou de parte dela para a preparação de uma composição farmacêutica anti-tumoral, sendo opcional a sua combinação com um ou mais agentes quimioterápicos. São também revelados: uma construção gênica para a expressão do referido ligante; um processo de produção; um processo de avaliação de células tumorais; e um método de sensibilização de tumores a quimioterápicos. A invenção proporciona também um novo modelo experimental in vivo e in vitro para o desenvolvimento/avaliação de agentes anti-tumorais. As composições farmacêuticas da invenção proporcionam ação anti-tumoral e possuem alta especificidade a células neoplásicas, resultando em menos citotoxicidade a células de divisão normal. Estas e outras vantagens da invenção se caracterizam como uma solução para os inconvenientes dos regimes terapêuticos quimioterápicos atualmente conhecidos
Latest bibliographic data on file with the International Bureau